Translate Bio, Inc. Common Stock
TBIO
TBIO was delisted on the 13th of September, 2021.
47 hedge funds and large institutions have $200M invested in Translate Bio, Inc. Common Stock in 2018 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 18 increasing their positions, 8 reducing their positions, and 10 closing their positions.
125% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 8
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
2% less funds holding
Funds holding: 48 → 47 (-1)
9% less capital invested
Capital invested by funds: $219M → $200M (-$19.1M)
10% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$4.07M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$3.18M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$2.42M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$832K |
| 5 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$566K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$2.58M |
| 2 |
BCPEM
Bain Capital Public Equity Management
Boston,
Massachusetts
|
-$2.36M |
| 3 |
Wells Fargo
San Francisco,
California
|
-$1.92M |
| 4 |
Millennium Management
New York
|
-$819K |
| 5 |
LCM
Laurion Capital Management
New York
|
-$650K |
TBIO Hedge Fund Activity: Q4 2018 in Review
47 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Translate Bio, Inc. Common Stock (TBIO) for Q4 2018, worth a combined $200M — down 8.7% from $219M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of TBIO and 9 opened new positions — a net loss of 1 holder — while 8 trimmed existing stakes and 18 added.
The largest buyer was BlackRock, adding an estimated $4.07M. The largest seller was ArrowMark Colorado Holdings, cutting an estimated $2.58M.
- 47 institutional investors held Translate Bio, Inc. Common Stock (TBIO) as of Q4 2018, down from 48 in Q3 2018.
- Funds reported $200M of Translate Bio, Inc. Common Stock stock for Q4 2018, down 8.7% quarter-over-quarter.
- 9 funds opened new Translate Bio, Inc. Common Stock positions in Q4 2018 and 10 closed out, a net change of -1 holder.
- The largest Translate Bio, Inc. Common Stock buyer in Q4 2018 was BlackRock, an estimated $4.07M added.
- The largest Translate Bio, Inc. Common Stock seller in Q4 2018 was ArrowMark Colorado Holdings, an estimated $2.58M sold.
Based on aggregated 13F filings for Q4 2018.